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Abstract
ABL tyrosine kinase inhibitors (TKI) like Imatinib, Dasatinib and Nilotinib are the gold
standard in conventional treatment of CML. However, the emergence of resistance
remains amajor problem. Alternative therapeutic strategies of ABLTKI-resistant CML
are urgently needed. We asked whether dual inhibition of BCR-ABL and Aurora
kinases A-C could overcome resistance mediated by ABL kinase mutations. We
therefore tested the dual ABL and Aurora kinase inhibitors PHA-739358 and R763/
AS703569 in Ba/F3- cells ectopically expressing wild type (wt) or TKI-resistant BCR-
ABL mutants. We show that both compounds exhibited strong anti-proliferative and
pro-apoptotic activity in ABL TKI resistant cell lines including cells expressing the
strongly resistant T315I mutation. Cell cycle analysis indicated polyploidisation, a
consequence of continued cell cycle progression in the absence of cell division by
Aurora kinase inhibition. Experiments using drug resistant variants of Aurora B
indicated that PHA-739358 acts on both, BCR-ABL and Aurora Kinase B, whereas
Aurora kinase B inhibition might be sufficient for the anti-proliferative activity
observed with R763/AS703569. Taken together, our data demonstrate that dual ABL
and Aurora kinase inhibition might be used to overcome ABL TKI resistant CML.
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Introduction
Chronic myeloid leukemia (CML) is a neoplastic disease of hematopoietic stem
cells triggered by the oncogene BCR-ABL. This fusion gene is the result of a
reciprocal translocation between chromosomes 9 and 22 and characterized by
constitutively activation of the BCR-ABL tyrosine kinase [1–3]. Since 2002, the
treatment of CML was revolutionized by the introduction of the ATP-competitive
inhibitor imatinib mesylate (IM, Gleevec), a BCR-ABL tyrosine kinase inhibitor
(TKI) with strong activity against the tyrosine kinases PDGFR, cKit and Abl. [4–
7]. The clinical use of Imatinib resulted in a significantly improved prognosis,
response rate, overall survival, and patient outcome in CML patients compared to
previous therapeutic regimens [8–10] and made it the gold standard in
conventional treatment of CML [11]. However, some CML patients in chronic
phase and a substantial proportion in accelerated phase and blast crisis are either
initially refractory to IM or loose IM sensitivity over time and experience relapse
[12–18]. Several mechanisms leading to IM resistance have been characterized
during the last years: most commonly, mutations in the BCR/ABL domain confer
IM resistance, either by altering IM binding characteristics or through indirect
modulation of kinase function, which are often associated with secondary
(acquired) resistance [19]. In this sense, kinase domain mutations are the most
frequently identified mechanism associated with relapse [20–26]. Substitution of
threonine with isoleucine at residue 315 (T315I gatekeeper mutation) is the most
prevalent mutation (14%) in IM- resistant patient [27] followed by the p-Loop
Mutation Y253F/H [17, 18]. Second-generation BCR-ABL TKIs nilotinib
(Tasigna) and dasatinib (Sprycel) showed significant activity in clinical trials in
patients resistant to imatinib therapy [28–35], except in those with the T315I
BCR-ABL gatekeeper mutation [20, 26, 36, 37]. However, the prognosis of
Imatinib refractory or intolerant chronic myelogenous leukemia and advanced
Ph+ acute lymphoblastic leukemia is still poor and new therapies are urgently
needed for those patients. Aurora kinase inhibitors (AKI) have recently emerged
as promising drugs in CML therapy, but it has not been entirely clear whether the
AKI apoptotic effect is due to BCR-ABL or Aurora kinase (A or B) inhibition and
whether dual inhibition of BCR-ABL and Aurora kinases could overcome
resistance mediated by ABL kinase mutations. Members of the Aurora kinase
family represent a new and promising target for anticancer therapeutics. Within
this family, Aurora kinases are highly homologous and conserved serine-threonine
protein kinases that play a key role in mitosis [38–42]. In mammalian cells Aurora
kinases are comprised of three family members: Aurora kinases A, B and C.
Aurora kinase A activity and protein expression increases from late G2-phase
through Mitosis and is required for centrosome-maturation and -separation,
mitotic entry, and spindle assembly [43]. Selective Aurora A inhibition due to
inhibition of Thr288 autoposphorylation leads to p53-dephosphorylation,
monopolar spindel formation with consecutive G2/M arrest and apoptosis [44–
47]. In contrast, Aurora kinase B is the catalytic part of the chromosomal
passenger complex (CPC) and critical not only for chromosomal condensation,
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segregation and bi-orientation but also for the spindle-assembly checkpoint and
final stages of cytokinesis [48–50]. Classically, selective Aurora B inhibition leads
to polyploidy and apoptosis [51–53] by inhibition of Histone-3 phosphorylation
at serine 10, a well-known down-stream-target of Aurora B. Expression of Aurora
C seems to be limited to the testis and its role has not been well defined yet. Both,
Aurora kinases A and B, have been linked to tumorigenesis with the frequent
finding of gene amplification and/or overexpression in several malignancies [54–
59] including CML, where it was shown that BCR-ABL regulates Aurora A [60]
and B inhibition (Figure S1). Furthermore, a functional cross-talk between Aurora
A and the p53- and p73-dependent apoptotic pathway in cancer cells was reported
[61].
The oncogenic role of Aurora kinases as well as their crucial role in cell cycle
division makes them an attractive potential target in anti-cancer therapy. A
growing number of Aurora kinase inhibitors have been developed during the past
years and entered successfully clinical phase I or II studies like MK-5108,
MLN8054, MLN8237, PHA-739358, AZD1152, AT92830, MSC1992371A, PF-
03814735 and R763/AS703569 [44, 45, 62–83].
Here we asked, whether dual inhibition of BCR-ABL and Aurora kinases could
overcome resistance mediated by ABL kinase mutations and therefore tested the
dual ABL and Aurora kinase inhibitors PHA-739358 and R763/AS703569 in BaF3-
cells expressing wild type (wt) or TKI-resistant BCR-ABL mutants. We show that
both compounds exhibited strong anti-proliferative and pro-apoptotic activity in
ABL TKI resistant cell lines including the T315I mutation. Furthermore, we were
able to identify a drug resistant Aurora B mutant that renders cells partially
resistant to PHA-739358 and R763/AS703569 in vitro with a cell-based screen of
resistance. With the help of this mutant, we could show, that Aurora B is an
important target with great potential in further anti-cancer drug development.
Materials and Methods
Inhibitors
PHA-739358 was kindly provided by Nerviano Medical Sciences, Milan, Italy. It
was dissolved at 20 mM in dimethyl sulfoxide (DMSO) and stored at 220 C̊.
Kinase inhibition profile and IC50s of PHA-739358 (Danusertib) are published by
Fancelli et al. [84, 85] R763/AS703569 was a kind gift from EMD-Serono
(Rockland, MA). A stock solution of R763/AS703569 (10 mmol/L; in DMSO) was
stored at 220 C̊. Kinase inhibition profile and IC50s of R763/AS703569 are
published by McLaughlin [86].
Cell culture, transfection and cell cycle synchronization
Parental Ba/F3 cells were obtained from DSMZ (Braunschweig, Germany). Ba/F3
cells were cultured under standard conditions in RPMI 1640 growth media
(Gibco, Karlsruhe, Germany) containing 10% fetal bovine serum, 200 U penicilin
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per mL, and 200 g streptomycin per mL (Gibco, Karlsruhe, Germany). IL3-
dependend Ba/F3 cells were supplemented with 2 ng/mL interleukin-3 (IL-3;
R&D, Wiesbaden, Germany). Ba/F3 p185wt cells were infected with retrovirus
(pBabe-puro, pBabe-AurA, pBabe-AurB) and puromycin-treated for selection.
For synchronisation in G0/1, cells were serum starved for 72 h in the presence of
0,5% FCS.
DNA constructs
BCR-ABL p185 was cloned as described previously [87]. Human Aurora A and B
wt cDNAs in pEGFP-C1 were obtained from E. Nigg (Martinsried, Germany).
Mutant forms of Aurora A and B were engineered in pEGFP-C1AurA/AurB using
the QuickChange Mutagenesis kit (Stratagene, Amsterdam, Netherlands),
subcloned in pCR-Blunt II-Topo or pCR-2.1-TOPO (Invitrogen, Karlsruhe,
Germany) and subsequently into pBabe-puro (Addagene, Cambridge, MA, USA).
All constructs were verified using automated sequencing.
Proliferation
Cell viability was assessed using a MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazoliumsalz)-based method
(CellTiter; Promega, Madison, WI). Briefly, 105 cells were seeded in triplicates in
96-well flat-bottom microtiter plates, treated as indicated and absorption
measured at 490 nM. The cellular IC50 value corresponds to the concentration of
50% growth inhibition. IC50 values were calculated by graphic exploration of the
dose-effect curve.
Cell cycle and apoptosis
For dynamic cell cycle analysis (BrdU-incorporation) cells were pulsed with 10
mM BrdU for 1 h and stained with anti-BrdU according to a standard protocol
(BD Biosciences). For static cell cycle analysis, cells were stained with propidium
iodide (25 mg/ml PI; 100 mg/ml RNAse in PBS; Sigma-Aldrich, Heidelberg,
Germany). Cell cycle distribution and apoptosis was determined by PI or two-
dimensional (fluorescein and PI) flow cytometry. Analysis of DNA content
occurred in the linear mode, apoptosis measuring in the logarithmic mode of the
FL2 channel. Results were quantified using FlowJo software (Tree Star Inc.,
Ashland, OR). Cells with DNA content ,2n were considered apoptotic (sub-G1).
Western blot
Cells were cultured for 2.5 h without (w.o.) or in the presence of inhibitor at the
indicated concentrations. After cell lysis, sonification, and measuring of the
protein concentration using BioRad Protein Assay (Biorad, Munich, Germany),
protein extracts were electrophoretically separated on SDS-PAGE gels and
immunoblotted with indicated antibodies. Anti-Aurora A, anti-Aurora B,
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Anti- pHistone-3 (Serine 10), and anti-b-Actin antibodies were obtained from
Sigma-Aldrich (Heidelberg, Germany), Anti-Flag (M2) antibody from Stratagene
(Heidelberg, Germany). Anti-Abl antibody (8E9) was purchased from BD
Biosciences (San Jose, CA), anti-STAT5 antibody (C-17) from Santa Cruz
Biotechnology Inc. (Heidelberg, Germany). Detection of phosphotyrosine was
performed using a mixture of the antibodys 4G10 (Millipore, Schwalbach,
Germany) and PY20 (BD Biosciences, San Jose, CA). pSTAT5 antibody was a kind
gift from T. Wheeler (Hamilton, New Zealand; Wheeler et al., 2001). Bands were
visualized using SuperSignal Chemoluminescence substrate (Pierce, Rockford,
USA).
Structural modeling
Graphical inspection and structural superposition was done with PyMOL
(DeLano W.L., The PyMOL Molecular Graphics System (2002), http://www.
pymol.org). Individual features of inhibitor interactions and geometries were
examined also using the electron density server and 3D-Ligand Interaction
analyzer, as linked in the PDB server pages.
Results
PHA-739358 and R763/AS703569 exert anti-proliferative effects in
BCR-ABL negative and positive Ba/F3 cells
To determine active concentrations of both inhibitors, we treated BCR-ABL
negative and positive Ba/F3 cells, including the IM-resistant BCR-ABL mutants
T315I, Y253F and F317L, with increasing concentrations of PHA-739358 and
R763/AS703569. PHA-739358 strongly inhibited cell proliferation in parental and
BCR-ABL expressing Ba/F3 cells in a dose-dependent manner. BCR-ABL
mutational status did not affect the anti-proliferative response to PHA-739358 or
R763/AS703569 (Figure 1A). Thus, sensitivity of individual BCR-ABL mutants to
PHA-739358 and R763/AS703569 did not correlate with the degree of resistance
to IM, and the highly imatinib resistant BCR-ABL/T315I mutation displayed
similar dose-response compared to BCR-ABL wt cells. Accordingly, IC50 values
were in a range of 150 nM for PHA-739358 and 10 nM for R763/AS703569,
independent of the BCR-ABL mutation status (Figure 1A). Thus, both inhibitors
exerted anti-proliferative effects in a dose-dependent manner and independent of
the BCR-ABL mutation status, with R763/AS703569 displaying significantly lower
IC50 values (Figure 1B).
PHA-739358 and R763/AS703569 effectively inhibit BCR-ABL and
Aurora Kinases
It has been described that AKIs can influence BCR-ABL kinase activity by
inhibiting BCR-ABL autophosphorylation and phosphorylation of its downstream
target STAT5. Therefore we asked whether the anti-proliferative effect of
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PHA-739358 and R763/AS703569 is a result of BCR-ABL or Aurora kinase
inhibition. Treatment with PHA-739358 (Figure 2A) or R763/AS703569
(Figure 2B) resulted in strong inhibition of BCR-ABL kinase activity in BCR-ABL
positive Ba/F3 cells. Effective concentrations for inhibition of BCR-ABL kinase
Figure 1. Aurora Kinase inhibitors PHA-739358 and R763/AS703569 compromise cell proliferation and viability at different concentrations in BCR-
ABL negative and positive Ba/F3 cells independent of the BCR-ABL mutation status. (A) Dose-effect curves for treatment with the indicated
concentrations of PHA-739358 and R763/AS703569 in Ba/F3 and Ba/F3 p185 cells, including the IM-resistant mutants T315I, Y253F and F317L, after 48 h.
Effects on cell proliferation were assessed by MTTassay. Shown is one representative experiment of three experiments performed. The percentage of cell
growth was normalized to the growth of untreated control cells. (B) Bar graph quantifying cell proliferation after exposure to 200 nM PHA-739358 or 15 nM
R763/AS703569 for 48 h. Untreated and DMSO-treated cells were used as controls. Shown is one representative experiment of three experiments
performed. Values are expressed as mean of triplicates ¡ SD. The difference between Ba/F3 p185 wt and BCR-ABL mutants is statistically significant. (C)
IC50 values of BCR-ABL positive and negative Ba/F3 cells, calculated from the results after 48 h of incubation with PHA-739358 or R763/AS703569.
doi:10.1371/journal.pone.0112318.g001
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activity and signaling were around 1000 nM and above for PHA-739358 and in the
range of 500 nM for R763/AS703569. Inhibition of BCR-ABL phosphorylation
occurred at similar concentrations for Ba/F3 p185wt, p185/T315I and p185/Y53F cells.
Surprisingly, higher concentrations of R763/AS703569 but not of PHA-739358 were
required to inhibit BCR-ABL phosphorylation in cells expressing BCR-ABL/F317L.
Thus, for PHA-739358 cellular IC50 values were in the range of the concentrations
where inhibition of BCR-ABL occurred, whereas -in case of R763/AS703569- IC50
values were more than 50-times lower than the concentrations needed for BCR-ABL
kinase inhibition. Taken together, these data provide evidence, that BCR-ABL kinase
inhibition might be, at least in part, responsible for the anti-proliferative effect of PHA-
739358, but not for R763/AS703569.
To assess inhibitory activity of PHA-739358 and R763/AS703569 on Aurora
kinases, phosphorylation of Histone-3 (H3) on Serine-10, a bone-fide Aurora B
target [50, 52, 85, 88], was determined. BCR-ABL positive cells exposed to PHA-
739358 (Figure 3A) or R763/AS703569 (Figure 3B) showed a distinct reduction of
phosphorylation on H3-Ser10, however at different concentrations. While with
PHA-739358 Aurora kinase inhibition was observed at 500 nM, 20 times lower
concentrations of R763/AS703569 were sufficient to obtain the same effect on H3-
ser10 phosphorylation. Thus, low concentrations of R763/AS703569 needed to
suppress Histone-3 phosphorylation corresponded to the cellular IC50 value.
Taken together, anti-proliferative effects of PHA-739358 can be likewise attributed
to BCR-ABL and Aurora kinase inhibition, whereas the anti-proliferative activity
seen with R763/AS703569 is exclusively due to Aurora kinase inhibition.
PHA-739358 and R763/AS703569 induce cell division failures and
apoptosis in BCR-ABL negative and positive Ba/F3 cells
Aurora Kinases A and B play key roles in regulation of mitotic processes [38, 40].
Inhibition of these kinases leads to mitotic defects and prevents cytokinesis
[39, 89]. In order to determine which Aurora kinase is the relevant target for the
used inhibitors, static cell cycle analyses were performed by flow cytometry.
Exposure to PHA-739358 at 500 nM or above induced endoreduplication and
generated polyploid cells with 8n and up to 16n DNA-content with subsequent
apoptosis (Figure 4A). We observed this effect not only in BCR-ABL positive cells
but also in parental, BCR-ABL negative cells. As expected, treatment with lower
concentrations of PHA-739358 did not change cell cycle profiles because of
insufficient Aurora kinase inhibition. R763/AS703569 abolished cell division in
BCR-ABL negative and positive Ba/F3 cells, resulting in accumulation of cells with
DNA content >4n (Figure 4B). Polyploidisation already became apparent at very
Figure 2. PHA-739358 and R763/AS703569 reduce BCR-ABL kinase activity at comparable concentrations
and independent of the BCR-ABL mutation status. Ba/F3 p185 wt and IM-resistant T315I, Y253F, and F317L
mutants cells were exposed to increasing concentrations of PHA-739358 (A) or R763/AS703569 (B) for 2.5 h and
assessed for phosphorylation status of BCR-ABL and its downstream target STAT5 by western blot analysis.
Untreated and DMSO treated cells were used as a controls.
doi:10.1371/journal.pone.0112318.g002
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low concentrations (10 nM R763/AS703569) and increased at higher concentra-
tions. Interestingly, a significant sub-G1 DNA content became apparent with
PHA-739358 at concentrations were inhibition of both Aurora as well as BCR-
ABL kinase was observed.
Identification of drug resistant Aurora kinase mutants
Our previous results hint to Aurora B as a relevant in-vitro target of PHA-739358 and
R763/AS703569. To confirm this assumption, we generated point mutations in
Aurora A and B with diminished inhibitor binding, while Aurora kinase activity was
not affected. Therefore, we performed in-silico modeling of the Inhibitor/Aurora
kinase-complex (Figure 5A, B). This analysis revealed two different positions in
Aurora A and B (Figure 5D): L210 in Aurora A, corresponding to L154 in Aurora B,
constitutes the gate keeper residue in a small hydrophobic pocket at the back of the
ATP-binding side, that can be utilized by small molecule ATP competitors but not by
ATP itself [90]. Studies from other protein kinases, where the corresponding
gatekeeper residues were mutated to bulkier residues resulted in abolished inhibitor
binding [91–93]. G216 in Aurora A (G160 in Aurora B) maps to the bottom of the
kinase hinge loop. Mutation of this residue into a bulkier amino acid was therefore
expected to create direct steric disablement to inhibitor binding without interfering
ATP binding. To follow our assumptions we introduced these mutations in Aurora A
(L210M, G216V) or Aurora B (L154M, G160V) by site-directed mutagenesis and
stably expressed them by transfecting Ba/F3 p185wt cells with pBabe-puro based
retroviruses encoding one of these constructs. Recombinant Flag-tagged Aurora A
and B constructs were expressed at equivalent levels, similar to the endogenous
proteins (Figure 5C).
Aurora B G160V mutant confers resistance to both inhibitors and
partially rescues Aurora B associated cell cycle functions
To investigate AKI resistance of the newly engineered Aurora kinase mutants,
phosphorylation of Histone-3 was examined after exposure to PHA-739358 or
R763/AS703569 (Figure 6 A, B). Interestingly, only AurB G160V expressing cells
showed a remarkable resistance to both compounds. Expression of AurA L210M,
AurA G216V, AurB L154M and several others Aurora mutations had no or
marginal effects (Figure S2). In addition, co-expression of Aurora constructs did
not affect BCR-ABL kinase inhibition (Figure S3).
To assess whether expression of the drug-resistant AurB G160V mutant
reverted in-vitro effects of PHA-739358 and R763/AS703569, we performed
Figure 3. Inhibition of Aurora kinase activity occurs at different concentrations of PHA-739358 and
R763/AS703569. Ba/F3 p185 wt, p185/T315I, p185/Y253F and p185/F317L cells were treated with indicated
concentrations of PHA-739358 (A) or R763/AS703569 (B) for 2.5 h. Aurora Kinase activity assessed by
phosphorylation status of Histone-H3 at Serine-10 was analyzed using immunoblotting. Control cells were left
untreated or exposed to DMSO.
doi:10.1371/journal.pone.0112318.g003
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proliferation assays and cell cycle analyses. Indeed, AurB 160V attenuated responses to
PHA-739358 and R763/AS703569 (Figure 7A, B) and increased IC50 values for both
drugs in p185 wt cells. Interestingly, cell cycle analysis revealed polyploidisation up to
16n in the presence of PHA-739358 or R763/AS703569 not only in control cells but also
in G160V expressing cells. Nevertheless, distinct polyploidisation also became apparent
with delay in the AurB G160V mutant: a considerable 8n population was observed after
24 h exposure to PHA-739358 or AS70356 in AurB G160V cells, whereas it was already
recognized 8 h after PHA-739358 and 4 h after AS70356 treatment in p185wt cells
(Figure 8 A, B). The apoptotic sub-G1 fraction increased over time, with the highest
value in control cells 48 h after PHA-739358 treatment.
To determine whether the observed effects were a consequence of Aurora B
overexpression or resulted from resistance due to the AurB G160V mutant,
dynamic 2-dimensional cell cycle analyses were performed. To this end, indicated
cell lines were first synchronized in G0 by serum deprivation for 72 h and then
reactivated by addition of 20% FCS in the presence of PHA-739358 or R763/
AS703569 for indicated timepoints. Treatment with PHA-739358 or R763/
AS703569 for 63 h resulted in a distinct G1-accumulation (2n peak) in AurB
G160V expressing cells but not in the control cells, indicating normal cell cycle
function in cells harboring the AurB G160V mutation (Figure 9A). Next, dynamic
cell cycle experiments were performed, and DNA synthesis was monitored by a
BrdU pulse after 62 h for 1 h. In control cells, R763/AS703569 reduced the
proportion of cells in S-Phase reduplicating their 2n DNA-content in favor of cells
reduplicating their 4n or 8n DNA-content (Figure 9B, left upper panel). Hence,
cells exited mitosis without dividing, returned to G1 with a 4n DNA-content, kept
on DNA-reduplicating and finally lost proliferative potential. Despite polyploi-
disation, expression of the AurB G160V mutation restored the proportion of cells
in S-Phase reduplicating their 2n DNA-content, constrained endoreduplication
and consequently partially rescued a normal cell cycle, demonstrating regenera-
tion of Aurora B Kinase activity (Figure 9B, right upper panel). Surprisingly,
PHA-739358 treatment of AurB G160V cells was not able to partially override
polyploidisation and endoreduplication (Figure 9B, lower panels).
Discussion
Imatinib has become the gold standard in the treatment of CML with excellent
and durable responses and minimal side effects [9, 10, 27, 94]. However, around
25% of patients treated with Imatinib do not respond to treatment or relapse after
Figure 4. Suppression of Aurora B kinase activity by PHA-739358 or R763/AS703569 inhibits cell
division and induces apoptosis in BCR-ABL negative and positive Ba/F3 cells. Ba/F3 and Ba/F3 p185
cells comprising the T315I, Y253F, and F317L mutations were exposed to the indicated concentration of PHA-
739358 (A) or R763/AS703569 (B). After 24 h analysis of DNA content and apoptotic fraction of PI-stained
cells were assessed by flow cytometry. Untreated cells served as control. Apoptosis was measured as the
percentage of cells of sub-G1 DNA content in the FL2 channel in a logarithmic scale.
doi:10.1371/journal.pone.0112318.g004
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initial response to Imatinib [95, 96]. 2nd generation ABL-kinase inhibitors such as
Nilotinib, Dasatinib, and Bosutinib proved to be effective against a variety of
Imatinib-resistant BCR-ABL mutations, but are ineffective against the BCR-ABL
T315I mutation [97–99]. Since PHA-739358 and R763/AS703569 are active
against Aurora kinases as well as BCR-ABL [84, 85, 100–102], we intended to
dissect the significance of aurora kinase versus BCR-ABL inhibition for anti-
proliferative and pro-apoptotic activity of AKIs in BCR-ABL transformed cells
harboring known BCR-ABL resistance mutations as well as mutations in Aurora
B. It has already been shown, that AKIs like VX-680 are active in patients with
BCR-ABL T315I leukemia [103, 104]. Within our study, we could show that
Aurora kinases are a valuable potential therapeutic target for kinase inhibitor
resistant CML. Both AKIs used in this study display a significant, dose-dependent
inhibition of proliferation and induction of apoptosis in BCR-ABL-negative and -
positive Ba/F3-cells, including those expressing clinically highly relevant BCR-ABL
mutations T315I, Y253F, and F317L. The BCR-ABL mutational status did not
affect the anti-proliferative activity of both compounds, and sensitivity to PHA-
739358 and R763/AS703569 did not correlate with the degree of imatinib
resistance. Both agents have already shown clinical activity in phase-1 trials in
patients with advanced solid tumors and hematological malignancies, including
patients with CML or Ph+ALL, resistant to ABL kinase inhibitor treatment and
patients harboring the T315I mutation [102, 105–109]. Crystal structure analysis
of ABL T315I kinase domain in complex with PHA-739358 provided a possible
structural explanation for its activity against ABL T315I. While mutation of
threonine to the bulkier AA isoleucine caused a steric hindrance and therewith
prevented binding of imatinib, PHA-739358 bound the active confirmation of the
kinase domain in the ATP-binding pocket and lacked steric hindrance imposed by
this substitution [100, 110]. Interestingly, kinase assays with PHA-739358 showed
even a higher affinity for the T315I mutation [100]. In our studies, we found no
compelling difference in activity of PHA-739358 or R763/AS703569 in Ba/F3 cells
expressing BCR-ABL wild-type or T315I: both inhibitors exerted anti-proliferative
and pro-apoptotic activity in all cell lines tested, but at different concentrations.
Previous studies indicated nanomolar activity of the used AKIs in this study in
preclinical models of solid tumors and hematologic malignancies including BCR-
ABL transformed cell lines [101, 111–114]. In our experiments, cellular IC50-
values of PHA-739358 were in the range of 150 nM, whereas IC50- values of R763/
AS703569 is 15-times lower concentrations in BCR-ABL transformed cell lines. In
Figure 5. Characterization of Aurora model system. Crystal structure was analyzed in order to identify residues, whose specific mutation should abolish
inhibitor binding while keeping Aurora kinase activity. (A) Superimposition of the CK2 crystal structure (green) with Aurora A (pink) - PHA-739358 (yellow)
complex crystal structure, showing the position of the point mutation L210 and G216. (B) Xenpus laevis Aurora B (green) and INCENP (turquoise) in
complex with AS7035369, showing the position of the point mutation L154 and G160. (C) Ba/F3 p185 wt cells were transfected with Babe-puro based
retrovirus encoding AurA L210M, AurA G216V, AurB L154M, or AurB G160V point mutations. Empty pBabe-vector was used as control. Selection was
accomplished with puromycin. Western blot analysis showing flag-tagged Aurora A and B expression similar to endogenous Aurora A/B protein levels. (D)
Amino acid sequence alignment of human Aurora kinase A and B. Mutated residues are framed. It is of note that the point mutations L210M and G216V in
Aurora A accord with L154M and G160V in Aurora B.
doi:10.1371/journal.pone.0112318.g005
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Figure 6. Aurora B G160Vmutant confers resistance to PHA-739358 and R763/AS703569.Western blot analysis probed to investigate the resistant potential of
Aurora A and B kinase mutants by detecting phospho-Histone-3 (serine 10) after 2.5 h exposure to increasing concentrations of PHA-739358 (A) or AS703569 (B).
Untreated and DMSO treated cells were used as control. For comparison untransfected Ba/F3 p185 wt cells were also included into the experiment.
doi:10.1371/journal.pone.0112318.g006
Role of Aurora B in BCR-ABL Induced Transformation
PLOS ONE | DOI:10.1371/journal.pone.0112318 November 26, 2014 15 / 27
addition, biologic activities of R763/AS-703569 occur at similar concentrations in
the context of different transforming oncogenes (i.e. Myc, BCR-ABL etc. [111]
and this work), indicating that Aurora kinases are the primary target in this
models. Previous studies with VX-680 already showed [60, 115], that BCR-ABL
inhibitory VX-680 concentrations do not appear to be necessary to induce anti-
CML activity in human Ph+ cell lines suggesting that the activity of VX-680 in
CML is mediated at least partly by Aurora- and not by ABL- inhibition. In
accordance, we observed anti-proliferative activity of R763/AS703569 at
concentrations where inhibition of Aurora kinases but not BCR-ABL kinase
occurred. Suppression of phospho-H3, a bone-fide Aurora B target, required
R763/AS703569 IC50-concentrations, whereas BCR-ABL-inhibition was observed
at much higher concentrations. The sufficiency of exclusive Aurora kinase
inhibition was confirmed by cell cycle analysis, where treatment with lower, BCR-
ABL not inhibiting R763/AS703569 concentrations, resulted in endoreduplication
and polyploid cell (.4n) accumulation as a consequence of continued cell cycle
progression in the absence of cell division. In vitro experiments with PHA-739358
revealed equivalent biologic results, although higher concentrations of PHA-
739358 were used, that inhibit Aurora kinases as well as BCR-ABL. However,
Figure 7. Drug-resistant Aurora B G160V mutant partly overcomes the anti-proliferative effect of PHA-739358 and R763/AS703569. (A) MTT assay
showing the anti-proliferative effect after treatment with increasing concentrations of PHA-739358 (upper panel) or R763/AS703569 (lower panel) for 48 h.
Percentage of cell growth was normalized to the growth of untreated control cells. Shown is one representative experiment of three experiments performed.
(B) Bar graph quantifying cell proliferation after exposure to 200 nM PHA-739358 (upper panel) or 15 nM R763/AS703569 (lower panel) for 48 h. Untreated
and DMSO-treated cells were used as control. Shown is one representative experiment of three experiments performed. Values show mean of triplicates ¡
SD. Difference between Ba/F3 p185 wt and AurB G160V expressing Ba/F3 p185 wt cells is statistically significant.
doi:10.1371/journal.pone.0112318.g007
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Figure 8. Expression of the resistant Aurora B G160V mutant partly rescues cell division failures after exposure to PHA-739358 and R763/
AS703569. Ba/F3 p185 wt and Aur B G160V expressing Ba/F3 p185 wt cells were cultured in the presence of 500 nM PHA-739358 (A) or 50 nM R763/
AS703569 (B), harvested at the indicated time points and analysed by flow cytometry to determine DNA content of propodium iodide (PI) stained cells.
doi:10.1371/journal.pone.0112318.g008
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identical cell cycle aberrations could be detected by treatment of BCR-ABL-
negative cells with both AKIs arguing for an exclusive Aurora kinase-mediated
and BCR-ABL-inhibition independent effect. These data corroborate the
hypothesis that cytotoxicity of PHA-739358 and AS-703569 primarily depends on
inhibition of Aurora kinases associated in-vitro effects.
Both Aurora kinases A and B have been linked to tumorigenesis and previous
publication highlight the importance of Aurora A inhibition: Kelly et al. showed
preclinical activity of Alisertib, a selective Aurora A inhibitor as a single agent or
in combination with nilotinib [76] in CML cells bearing wild-type or T315I BCR-
ABL. Moreover, Yuan et al showed that CML resistance can be overcome with
specific Aurora A gene knockdown. Next to Aurora A knockdown, this study used
the AKI S1451, which spared Histone H3 Ser10 phosphorylation and polyploidy
[60], suggesting a specific Aurora A inhibition. It is worth noting, that it could be
recently shown, that BCR-ABL induces upregulation of both Aurora kinases A
and B via AKT in BCR-ABL positive cells [116], suggesting an impact of both
Aurora isoforms in CML cells. Moreover, Mancini et al demonstrated, that VX-
680 induced Gadd45a transcription and thereby recruitment of Oct-1 transcrip-
tion factor at critical promoter regions for gene transcription and covalent
modifications of histone H3 (S10 de-phosphorylation, K9 de-methylation and
K14 acetylation) [60]. Recent studies have revealed that dephosphorylation of
Histone-3 and accumulation of polyploid cells is based on suppression of Aurora
kinase B activity [50–52, 117–120]. Our experiments demonstrated the described
Aurora B inhibition phenotype upon PHA-739358 and R763/AS703569
treatment, suggesting that Aurora B may also be a relevant target for both
compounds. To confirm this hypothesis, we designed different Aurora B point
mutations in the ATP-binding site mediating resistance and were able to identify a
PHA-739358 and R763/AS703569 resistant mutant (Aurora B G160V). This
mutant shows significant resistance in vitro and in vivo and is able to attenuate
the anti-proliferative capacity of both inhibitors in BCR-ABL positive cells,
demonstrated by a significant increase of IC50- values and a delay in Histone-3
dephosphorylation. Cell cycle analysis detected active Aurora B kinase in the
presence of AKIs in Ba/F3 p185 wt Aurora B G160V cells. These findings further
substantiate Aurora B kinase inhibition as one cause of the anti-proliferative and
pro-apoptotic effects of PHA-739358 and R763/AS703569. Along this line,
development of drug resistance arising in cell-cycle kinases is conceivable. Taylor
et colleagues [121] reported about acquired point mutations in the Aurora B
kinase domain after prolonged exposure to ZM447439. Expression of these
mutant Aurora B alleles rendered cancer cell lines resistant to ZM447439 and
Figure 9. Aurora B G160V mutant constrains endoreduplication and rescues partly a normal cell cycle. Asynchronously growing Ba/F3 p185 wt cells
and Aurora B G160V expressing Ba/F3 p185 wt cells (AS) were serum starved for 72 h (SS), then reactivated with 20% serum and simultaneously treated
with 500 nM PHA-739358 or 50 nM R763/AS703569 for 63 h. (A) Time course for DNA synthesis after G0-release and exposure to 50 nM R763/AS703569.
(B) DNA synthesis was monitored by BRDU pulse for 1 h after 63 h of culture. Only in the presence of 50 nM R763/AS703569 (upper panel) and not of
500 nM PHA-739358 (lower pannel) Aurora B G160V mutant restores the 2n population (arrow), demonstrating regeneration of Aurora B kinase activity.
doi:10.1371/journal.pone.0112318.g009
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several other AKIs. However, kinase-independent mechanisms of AKI resistance
are also possible. In PHA-739358 resistant cells, overexpression of the Abcg2
efflux carrier could be identified as a potential mechanism of drug resistance
[122]. This knowledge should have important implications for future drug-
development, focusing on identifying compounds that target mutated Aurora
kinases.
Taken together, our data demonstrate that dual ABL and Aurora kinase
inhibition can be used to overcome ABL TKI resistant CML. Interestingly, cellular
effects of PHA-739358 and R763/AS703569 in BCR-ABL positive cells are
primarily mediated by functional inhibition of Aurora kinase B strongly
suggesting that Aurora kinases and not BCR-ABL is the biologically relevant target
in TKI-resistant Ph+ leukemia and that Aurora B may be an essential and
attractive target in CML cells.
Supporting Information
Figure S1. Expression of Aurora kinase A and B is regulated by BCR-ABL
activity. Ba/F3 p185 wt cells were treated with 2 mM Imatinib for 24 and
48 hours, harvested and determined by western blot analysis with the indicated
antibodies. GAPDH served as loading, PY as imatinib control.
doi:10.1371/journal.pone.0112318.s001 (JPG)
Figure S2. Characterization of further mutants provides no evidence of higher
resistance to PHA-739358 or R763/AS703569 than Aurora B G160V mutant.
doi:10.1371/journal.pone.0112318.s002 (TIFF)
Figure S3. Expression of Aurora kinase mutations in BCR-ABL positive cells
has no influence on the BCR-ABL kinase inhibition concentration of PHA-
739358 and R763/AS703569. Ba/F3 p185 wt cells and the indicated Aurora A and
B kinase mutants were treated with increasing concentrations of PHA-739358 (A)
or R763/AS703569 (B) for 2.5 h. Phosphorylation levels of BCR-ABL and its
downstream target STAT5 were determined by western blot analysis. Untreated
and DMSO treated cells served as a control.
doi:10.1371/journal.pone.0112318.s003 (JPG)
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